The Axial Spondyloarthritis market is projected to register a CAGR of 7.37% during the forecast period (2022 - 2027).
With the increasing COVID-19 cases worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. Although COVID-19 severely affects the respiratory system, it has created multiple uncertainties regarding rheumatic diseases or their treatment with regard to the susceptibility to or severity of the viral disease. The coronavirus disease 2019 (COVID-19) pandemic has been especially challenging for patients with inflammatory diseases, including spondyloarthritis (SpA). Although numerous studies have addressed how a COVID-19 infection affects patients with rheumatic diseases, the conclusions from these reports have not been consistent. A study published in The Journal of Rheumatology in 2022 captured responses from 4723 subjects with SpA and 450 household contacts of these subjects showed that the COVID-19 pandemic created multiple uncertainties regarding rheumatic diseases or their treatment with regard to the susceptibility or severity of the viral disease.
There has been increased research and development going on for rheumatic diseases during the pandemic. For instance, in February 2021, EULAR, the European Alliance of Associations for Rheumatology, launched COVAX. This is a doctor-reported registry to collect information about COVID vaccination in people with both inflammatory and non-inflammatory rheumatic and musculoskeletal diseases (RMDs).
Certain factors that are driving the market growth include improvements in awareness which result in the increased patient pool that proves to be positive upfront for the Axial spondyloarthritis market and helps patients to try new interventions. There are several governmental and non-governmental organizations coming up to raise awareness among the general population about the condition. There are several initiatives taking place to advocate for people about the diagnosis and treatment of the same. Some of the initiatives include Rheumatoid Arthritis Awareness Day, supported by groups such as Arthritis National Research Foundation, which is held on February 2 each year. In addition to this, Rheumatic Disease Awareness Month (RDAM) is held in September in the United States. As a result of increased awareness, people are aware of the diagnosis, and hence, the overall market will boost in the forecasted period.
Additionally, as part of the Bone and Joint Week celebration in October 2021, Novartis announced the renewal of its partnership with the Axial Spondyloarthritis Association of the Philippines (ASAPh) and Philippine Rheumatology Association (PRA) to raise awareness of Axial Spondyloarthritis (axSpA) early diagnosis and treatment.
The advent of biologic drugs has transformed the management of patients with axial spondyloarthritis. An increase in biologics is another factor that can drive the market. As per the American College of Rheumatology, Non-steroidal anti-inflammatory drugs (commonly called NSAIDs) offer symptom relief for most patients by reducing pain and swelling. Other medicines called biologics, including anti-TNF drugs (TNF blockers) and anti-IL-17 drugs (IL-17 blockers), are effective in patients who do not respond well enough to NSAIDs. The first lines of treatment are the NSAIDs, such as naproxen, ibuprofen, meloxicam, or indomethacin. Biologic medicines are manufactured within a living system, and target specific molecules believed to be involved in axial SpA. They are made up of genetically engineered proteins and are very large, complex molecules. The National Institute for Health and Care Excellence (NICE) has produced written national guidelines about prescribing anti-TNF therapy and anti-IL-17A that must be followed.
In addition to this, until very recently, there were five licensed anti-TNF drugs (adalimumab, certolizumab, etanercept, golimumab, and infliximab) for the indication of ankylosing spondylitis and four (adalimumab, etanercept, certolizumab, and golimumab) for the indication of Non-Radiographic Axial Spondyloarthritis (in the United States, only certolizumab was approved for the indication of Non-Radiographic Axial Spondyloarthritis). The IL-17 blocker secukinumab has been approved by both the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for the indication of ankylosing spondylitis. Ixekizumab was initially (2019) approved by the FDA for ankylosing spondylitis, and in July 2020, the FDA expanded the approval of ixekizumab to include Non-Radiographic Axial Spondyloarthritis; almost simultaneously, the EMA also approved ixekizumab for the treatment of both ankylosing spondylitis and Non-Radiographic Axial Spondyloarthritis.
The nonsteroidal anti-inflammatory drug class Segment occupies a major share of the market over the forecast period (2022 - 2027). Nonsteroidal anti-inflammatory drugs (NSAIDs) are highly effective and most commonly used in the treatment of axial spondyloarthritis.
Treatment for axSpA usually starts with nonsteroidal anti-inflammatory drugs (NSAIDs). Nonsteroidal anti-inflammatory drugs (NSAIDs) are highly effective against the major symptoms of axSpA (pain and stiffness) and may have disease-modifying properties, including retarding the progression of structural damage in the spine. Therefore, NSAIDs, unless contraindicated, are the treatment of choice for the majority of patients with axSpA. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen (Naprosyn) and indomethacin (Indocin and Tivorbex), are the medications preferred by doctors.
As per the Spondylitis Association of America, Ibuprofen is a generic NSAID and is found in over-the-counter pain relievers such as Advil and Motrin that are used for the treatment of Axial Spondyloarthritis. In addition to this, The 2019 American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) recommendations similarly advise that adults with active axSpA receive continuous NSAIDs over on-demand NSAIDs. However, in adults with stable axSpA, on-demand treatment with NSAIDs is recommended over continuous treatment.
North America is Expected to Hold a Significant Share in the Market and is expected to do the same in the Forecast Period 2022 - 2027.
The United States is the most affected country across the world, as there are higher numbers of patients suffering from Axial spondyloarthritis and higher in the North America region as the patient population is increasing compared to other countries.
North America is expected to hold a major market share in the global Axial spondyloarthritis market due to a rise in awareness, increasing prevalence in this region, and improved diagnosis. As per a study published in AJMC, approximately 1.5 million Americans are affected by axial spondyloarthritis, with estimates of axial spondyloarthritis prevalence ranging from 0.9% to 1.4%. Typically, axial spondyloarthritis affects the younger spondyloarthritis patient population, with an average age of symptom onset of 28 years. Additionally, as per the study published in Europe PubMed Central, the prevalence of ankylosing spondylitis ranged from 9 to 30 per 10,000 persons, which is lower than previous estimates. The progression of patients with non-radiographic axial spondyloarthritis to ankylosing spondylitis is slow, with estimates of 5.1% in 5 years and 19% in 10 years.
Moreover, high expenditure on healthcare, especially in the United States and Canada, along with increased awareness about the disease, is fueling the growth of the overall regional market to a large extent.
The axial spondyloarthritis market is fragmented, competitive, and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Johnson & Johnson, UCB, Amgen, Novartis Pharmaceuticals Corporation, Eli Lilly and Company, Kyowa Kirin, AbbVie, Acelyrin, and Pfizer.
This product will be delivered within 2 business days.
With the increasing COVID-19 cases worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. Although COVID-19 severely affects the respiratory system, it has created multiple uncertainties regarding rheumatic diseases or their treatment with regard to the susceptibility to or severity of the viral disease. The coronavirus disease 2019 (COVID-19) pandemic has been especially challenging for patients with inflammatory diseases, including spondyloarthritis (SpA). Although numerous studies have addressed how a COVID-19 infection affects patients with rheumatic diseases, the conclusions from these reports have not been consistent. A study published in The Journal of Rheumatology in 2022 captured responses from 4723 subjects with SpA and 450 household contacts of these subjects showed that the COVID-19 pandemic created multiple uncertainties regarding rheumatic diseases or their treatment with regard to the susceptibility or severity of the viral disease.
There has been increased research and development going on for rheumatic diseases during the pandemic. For instance, in February 2021, EULAR, the European Alliance of Associations for Rheumatology, launched COVAX. This is a doctor-reported registry to collect information about COVID vaccination in people with both inflammatory and non-inflammatory rheumatic and musculoskeletal diseases (RMDs).
Certain factors that are driving the market growth include improvements in awareness which result in the increased patient pool that proves to be positive upfront for the Axial spondyloarthritis market and helps patients to try new interventions. There are several governmental and non-governmental organizations coming up to raise awareness among the general population about the condition. There are several initiatives taking place to advocate for people about the diagnosis and treatment of the same. Some of the initiatives include Rheumatoid Arthritis Awareness Day, supported by groups such as Arthritis National Research Foundation, which is held on February 2 each year. In addition to this, Rheumatic Disease Awareness Month (RDAM) is held in September in the United States. As a result of increased awareness, people are aware of the diagnosis, and hence, the overall market will boost in the forecasted period.
Additionally, as part of the Bone and Joint Week celebration in October 2021, Novartis announced the renewal of its partnership with the Axial Spondyloarthritis Association of the Philippines (ASAPh) and Philippine Rheumatology Association (PRA) to raise awareness of Axial Spondyloarthritis (axSpA) early diagnosis and treatment.
The advent of biologic drugs has transformed the management of patients with axial spondyloarthritis. An increase in biologics is another factor that can drive the market. As per the American College of Rheumatology, Non-steroidal anti-inflammatory drugs (commonly called NSAIDs) offer symptom relief for most patients by reducing pain and swelling. Other medicines called biologics, including anti-TNF drugs (TNF blockers) and anti-IL-17 drugs (IL-17 blockers), are effective in patients who do not respond well enough to NSAIDs. The first lines of treatment are the NSAIDs, such as naproxen, ibuprofen, meloxicam, or indomethacin. Biologic medicines are manufactured within a living system, and target specific molecules believed to be involved in axial SpA. They are made up of genetically engineered proteins and are very large, complex molecules. The National Institute for Health and Care Excellence (NICE) has produced written national guidelines about prescribing anti-TNF therapy and anti-IL-17A that must be followed.
In addition to this, until very recently, there were five licensed anti-TNF drugs (adalimumab, certolizumab, etanercept, golimumab, and infliximab) for the indication of ankylosing spondylitis and four (adalimumab, etanercept, certolizumab, and golimumab) for the indication of Non-Radiographic Axial Spondyloarthritis (in the United States, only certolizumab was approved for the indication of Non-Radiographic Axial Spondyloarthritis). The IL-17 blocker secukinumab has been approved by both the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for the indication of ankylosing spondylitis. Ixekizumab was initially (2019) approved by the FDA for ankylosing spondylitis, and in July 2020, the FDA expanded the approval of ixekizumab to include Non-Radiographic Axial Spondyloarthritis; almost simultaneously, the EMA also approved ixekizumab for the treatment of both ankylosing spondylitis and Non-Radiographic Axial Spondyloarthritis.
Key Market Trends
The Non-steroidal anti inflammatory drug class Segment is Expected to Hold a Major Market Share in the Axial spondyloarthritis Market
The nonsteroidal anti-inflammatory drug class Segment occupies a major share of the market over the forecast period (2022 - 2027). Nonsteroidal anti-inflammatory drugs (NSAIDs) are highly effective and most commonly used in the treatment of axial spondyloarthritis.
Treatment for axSpA usually starts with nonsteroidal anti-inflammatory drugs (NSAIDs). Nonsteroidal anti-inflammatory drugs (NSAIDs) are highly effective against the major symptoms of axSpA (pain and stiffness) and may have disease-modifying properties, including retarding the progression of structural damage in the spine. Therefore, NSAIDs, unless contraindicated, are the treatment of choice for the majority of patients with axSpA. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen (Naprosyn) and indomethacin (Indocin and Tivorbex), are the medications preferred by doctors.
As per the Spondylitis Association of America, Ibuprofen is a generic NSAID and is found in over-the-counter pain relievers such as Advil and Motrin that are used for the treatment of Axial Spondyloarthritis. In addition to this, The 2019 American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) recommendations similarly advise that adults with active axSpA receive continuous NSAIDs over on-demand NSAIDs. However, in adults with stable axSpA, on-demand treatment with NSAIDs is recommended over continuous treatment.
Geography Trends
North America is Expected to Hold a Significant Share in the Market and is expected to do the same in the Forecast Period 2022 - 2027.
The United States is the most affected country across the world, as there are higher numbers of patients suffering from Axial spondyloarthritis and higher in the North America region as the patient population is increasing compared to other countries.
North America is expected to hold a major market share in the global Axial spondyloarthritis market due to a rise in awareness, increasing prevalence in this region, and improved diagnosis. As per a study published in AJMC, approximately 1.5 million Americans are affected by axial spondyloarthritis, with estimates of axial spondyloarthritis prevalence ranging from 0.9% to 1.4%. Typically, axial spondyloarthritis affects the younger spondyloarthritis patient population, with an average age of symptom onset of 28 years. Additionally, as per the study published in Europe PubMed Central, the prevalence of ankylosing spondylitis ranged from 9 to 30 per 10,000 persons, which is lower than previous estimates. The progression of patients with non-radiographic axial spondyloarthritis to ankylosing spondylitis is slow, with estimates of 5.1% in 5 years and 19% in 10 years.
Moreover, high expenditure on healthcare, especially in the United States and Canada, along with increased awareness about the disease, is fueling the growth of the overall regional market to a large extent.
Competitive Landscape
The axial spondyloarthritis market is fragmented, competitive, and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Johnson & Johnson, UCB, Amgen, Novartis Pharmaceuticals Corporation, Eli Lilly and Company, Kyowa Kirin, AbbVie, Acelyrin, and Pfizer.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Johnson and Johnson
- AbbVie
- Amgen
- Novartis Pharmaceuticals Corporation
- Eli Lilly and Company
- UCB
- Kyowa Kirin
- AbbVie
- Acelyrin
- Pfizer
Methodology
LOADING...
